Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy

Restoring IL-2 to its cancer immunotherapy glory

(2021) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma

(2021) Ahmad A Tarhini et al.   Immunotherapy

Lipid nanoparticles for mRNA delivery

(2021) Xucheng Hou et al.   Nature Reviews Materials

Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

(2021) Wenqing Li et al.   Nature Communications

CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma

(2021) Fatemeh Talebian et al.   Frontiers in Cell and Developmental Biology

Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours

(2020) Aslan Mansurov et al.   Nature Biomedical Engineering

Intra-Tumoral Delivery of IL-27 Using Adeno-Associated Virus Stimulates Anti-tumor Immunity and Enhances the Efficacy of Immunotherapy

(2020) Aiyan Hu et al.   Frontiers in Cell and Developmental Biology

Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment

(2020) Susannah L Hewitt et al.   CLINICAL CANCER RESEARCH

Interferons α and β in cancer: therapeutic opportunities from new insights

(2019) Ernest C. Borden   NATURE REVIEWS DRUG DISCOVERY

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer

(2019) Chengxiang Zhang et al.   Nano Research

Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy

(2019) Noor Momin et al.   Science Translational Medicine

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile

(2019) Qingnan Zhao et al.   Journal for ImmunoTherapy of Cancer

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma

(2019) Shailender Bhatia et al.   CLINICAL CANCER RESEARCH

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors

(2018) Jiemiao Hu et al.   CLINICAL CANCER RESEARCH

Cytokines in Cancer Immunotherapy

(2017) Thomas A. Waldmann   Cold Spring Harbor Perspectives in Biology

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma

(2016) Praveen K. Bommareddy et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+Melanoma

(2016) Jin-Qing Liu et al.   JOURNAL OF IMMUNOLOGY

Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA

(2016) Bin Li et al.   Scientific Reports

Potential clinical application of interleukin-27 as an antitumor agent

(2015) Takayuki Yoshimoto et al.   CANCER SCIENCE

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

(2015) L. Zhang et al.   CLINICAL CANCER RESEARCH

An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo

(2015) Bin Li et al.   NANO LETTERS

Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma

(2015) J. J. Luke et al.   Cancer Immunology Research

Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth

(2015) Zhenzhen Liu et al.   OncoImmunology

Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma

(2014) F. Stephen Hodi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

(2013) Michael A. Curran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Critical Role of Dendritic Cell-Derived IL-27 in Antitumor Immunity through Regulating the Recruitment and Activation of NK and NKT Cells

(2013) J. Wei et al.   JOURNAL OF IMMUNOLOGY

Interleukin-27 Signaling Promotes Immunity against Endogenously Arising Murine Tumors

(2013) Karlo D. T. Natividad et al.   PLoS One

IL-27 enhances the survival of tumor antigen-specific CD8+T cells and programs them into IL-10-producing, memory precursor-like effector cells

(2012) Zhenzhen Liu et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo

(2011) Brian R. Rosborough et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

(2010) S. P. Kerkar et al.   CANCER RESEARCH

IL-12 and IL-27 Sequential Gene Therapy via Intramuscular Electroporation Delivery for Eliminating Distal Aggressive Tumors

(2010) Shiguo Zhu et al.   JOURNAL OF IMMUNOLOGY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

(2009) Johanna K. Morales et al.   BREAST CANCER RESEARCH AND TREATMENT

Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity

(2008) Yukari Shinozaki et al.   INTERNATIONAL JOURNAL OF CANCER